首页 | 本学科首页   官方微博 | 高级检索  
     

As_2O_3干预口腔鳞癌A431细胞EGFR表达的研究
引用本文:张令波,;张斌,;胡伟平,;郭拴龙,;胡那日苏,;付兆臣,;高丽,;吕智勇. As_2O_3干预口腔鳞癌A431细胞EGFR表达的研究[J]. 生物磁学, 2014, 0(18): 3405-3409
作者姓名:张令波,  张斌,  胡伟平,  郭拴龙,  胡那日苏,  付兆臣,  高丽,  吕智勇
作者单位:[1]哈尔滨医科大学附属第二医院口腔科,黑龙江哈尔滨150086; [2]哈尔滨医科大学硬组织发育和再生研究所,黑龙江哈尔滨150086; [3]黑龙江省医学科学院,黑龙江哈尔滨150086; [4]中俄合作哈尔滨医科大学硬组织发育与再生研究所,黑龙江哈尔滨150086;
基金项目:国家自然基金面上项目(81170960);国家自然基金青年项目(81101086); 黑龙江省科技厅攻关项目(GC12C303-2); 哈尔滨医科大学附属第二医院青年启动基金(QN2010-04)
摘    要:目的:研究三氧化二砷(As2O3)对人口腔鳞癌A431细胞生长的抑制作用,探讨其抗肿瘤的机制。方法:合成特异性靶向到肿瘤细胞表面表皮生长因子受体(EGFR)的近红外荧光分子对比剂EGF-Cy5.5,验证试剂合成的靶向特异性。口腔鳞状细胞癌A431细胞系暴露于浓度分别为0μM,0.5μM,2.5μM和5.0μM的三氧化二砷溶液中0,24 h,48 h和72 h。共聚焦显微镜、流式细胞仪及免疫组化证实EGFR的表达水平,上述实验均测量三次,结果取平均值。结果:EGF-Cy5.5靶向荧光对比剂的标记率为68%~70%。对比对照组,越高浓度的三氧化二砷处理的肿瘤细胞其获得的细胞荧光信号强度越小,这与药物浓度越高细胞表面表达EGFR的量越少相一致。流式细胞仪显示,在72小时,作用于细胞的三氧化二砷药物浓度分别为0.5μM,2.5μM,和5.0μM,其相对应获得的细胞EGFR表达量分别为57.28±3.2%(P〈0.05),29.91±2.2%(P〈0.01)和10.73±2.4%(P〈0.01),明显低于对照组的细胞EGFR表达量74.42±1.8%,(P〈0.05)。结论:本研究应用近红外荧光分子成像的方法体外检测口腔鳞状细胞癌A431的EGFR表达水平,实验证明三氧化二砷对其EGFR具有明显的抑制作用,且抑制作用具有时间-剂量依赖性。

关 键 词:三氧化二砷(As2O3)  口腔鳞状细胞癌(OSCC)  表皮生长因子受体(EGFR)  近红外光学成像(NIR)

Effects of Arsenic Trioxide on EGFR Expression of Oral Squamous Cell Carcinoma A431 Cell
Affiliation:ZHANG Ling-bo, ZHANG Bin, HU Wei-ping, GUO Shuan-long, HU Nadsu, FU Zhao-chen, GA O Li, L V Zhi-yong (1 Stomatology Department, 2nd Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, 150086, China; 2 Institute of Hard Tissue Development and Regeneration, 2nd Afllliated Hospital, Harbin Medical University, Harbin, Heilongjiang, 150086, China; 3 Heilongjiang Academy of Medical Sciences, Haebin, Heilongjiang, 150086; 4 Sino-Russian Institute of Hard Tissue Development and Regeneration)
Abstract:Objective: This study was to investigate the inhibitory effect and mechanism of Arsenic Trioxide(As2O3) on oral squamous cell carcinoma A431 cell. Methods: EGF-Cy5.5 was synthesized according to our previous report and was used as a tumor cellular EGFR specific imaging agent. A431 in vitro were exposed to 0 μM, 0.5 μM, 2.5 μM, or 5 μM of As2O3for 0 h, 24 h, 48 h and 72 h. Confocal microscopy and flow cytometry and cell immunohistochemical staining confirmed EGFR expression. All the studies were measured 3 times and the results were presented as mean. Results: The labeling rate of targeted fluorescent contrast agent EGF-Cy5.5 was 68 % to 70 %. In vitro, less intense cellular fluorescence signal was observed in cells treated with higher concentration of As2O3compared with control cells, consistent with the lower levels of EGFR expression in treatment cells. Flow cytometry showed the cellular EGFR expression was 57.28±3.2 %(P〈0.05), 29.91±2.2 %(P〈0.01), and 10.73±2.4 %(P〈0.01) in cells treated with 0.5 μM, 2.5 μM, and 5.0 μM As2O3, respectively, which were significant lower than the control group(74.42±1.8 %, P〈0.05) at 72 hours. Conclusion: This study assessed in vitro by NIR molecular imaging that the EGFR expression of OSCC A431 cell and demonstrates the inhibition effect of OSCC response to As2O3treatment in dose-dependent characteristics.
Keywords:Arsenic Trioxide (As2O3)  Oral Squamous Cell Carcinoma (OSCC)  Epidermal Growth Factor Receptor (EGFR)  NearInfrared Imaging (NIR)
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号